|
Pakistan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Pakistan Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Pakistan.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Pakistani pharmaceutical and healthcare industry.
Competitive intelligence, Pakistani pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Pakistani market.
The Pakistan Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Pakistan Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Pakistani pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Pakistan to test other views – a key input for successful budgeting and strategic business planning in the Pakistani pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Pakistani Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Pakistan.
- Exploit The Latest Competitive Pakistani Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Pakistan.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Pakistan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Pakistan Pharmaceutical Industry SWOT |
| Pakistan Political SWOT |
| Pakistan Economic SWOT |
| Pakistan Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Business Environment Ranking |
| Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q209 |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Market Summary |
| Regulatory Regime |
| Intellectual Property Regime |
| Shortcomings of The Intellectual Property Environment |
| Table: Healthcare And Pharmaceutical Companies That Are Members Of The American Business Council Of Pakistan |
| Counterfeit Drugs |
| Pricing and Reimbursement Regime |
| Recent Pricing and Reimbursement Developments |
Chapter - Industry Trends And Developments |
| Epidemiology |
| Healthcare System |
| Table: Pakistan – Key Healthcare Statistics, 2007 (‘000 people, unless otherwise stated) |
| Pharmaceutical Sector |
| Traditional Medicine |
| Research and Development |
| Retail Sector |
| International Co-operation |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Pakistan – Drug Expenditure Indicators, 2003-2013 |
| Key Growth Factors – Industry |
| Table: Pakistan – Health Expenditure Indicators, 2003-2013 |
| Key Growth Factors – Macroeconomic |
| Table: Pakistan - Economic Activity |
| Prescription Market Forecasts |
| Table: Pakistan – Prescription Market Indicators, 2003-2013 (PKRmn unless otherwise stated) |
| OTC Market Forecast |
| Table: Pakistan – OTC Drugs Market Indicators, 2003-2013 (PKRmn unless otherwise stated) |
| Patented Product Market Forecast |
| Table: Pakistan – Patented Drugs Market Indicators, 2003-2013 |
| Generic Drug Market Forecast |
| Table: Pakistan – Generic Drugs Market Indicators, 2003-2013 |
| Export/Import Forecasts |
| Table: Pakistan – Pharmaceutical Trade Indicators, 2003-2013 (US$mn) |
| Other Healthcare Data Forecasts |
| Table: Pakistan – Other Healthcare Indicators, 2003-2013 (per ‘000 population, unless otherwise stated) |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Table: Pakistan's Pharmaceutical Market In Q406 |
| Recent Pharmaceutical Industry Developments |
Chapter - Company Profiles |
| Leading Multinational Manufacturers |
| GlaxoSmithKline |
| Pfizer |
| Abbott Laboratories |
| Novartis |
| Sanofi-Aventis |
| Merck & Co |
| Wyeth |
| Domestic Manufacturers |
| Hilton Pharma |
| Efroze Chemical Industries |
| Ferozsons Laboratories |
| Pacific Pharmaceuticals |
Chapter - Country Snapshot: Pakistan Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education and Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Table: Employment Indicators, 2001-2006 |
| Section 3: Labour Market And Spending Power |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Manufacturing Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Pakistan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The value of Pakistan’s pharmaceutical market is forecast to reach US$3.34bn by 2013, representing a compound annual growth rate (CAGR) of 10.55%. This rate of expansion is one of the highest in our coverage universe. However, it is at significant risk due to the escalation of political unrest and terrorist activity in Pakistan. A downgrade is very likely in the Q309 update of this report. Combined sales of generic drugs, patented products and over-the-counter (OTC) medicines were calculated to be US$2.02bn in 2008.
During February 2009, Khawaja Shah-zeb Akram, vice chairman of Pakistan's Industrial and Traders Associations Front (PIAF), stated that the government should take significant steps to support domestic pharmaceutical companies. He also added that the pharmaceutical sector has the capability to generate huge revenue through exports if the state promotes a business-friendly environment.
Prices of pharmaceuticals sold in Pakistan are determined by an advisory committee in the Ministry of Health (MoH). The body uses a system of 'price mechanism' and 'standard formula', which takes input costs into account. However, it appears that this approach is not working. Some drug-makers have unilaterally increased the prices of their products following hikes in the cost of raw materials, fuel and electricity, and the depreciation of the rupee.
Regulations are in place but frequently not adhered to. For example, it was revealed in December 2008 that only a fifth of drug-makers in Lahore were destroying their waste – such as expired medicines and toxic raw materials – in incinerators. They were therefore infringing the Hospital Waste Management Rules (HWMR).
During January 2009, the government of Punjab in Pakistan was planning to put into effect Drug Rules 2009 in order to curtail counterfeit drugs. As per the Drug Act of 1976, wholesalers were not given any place in the drug supply chain. However, in the new Drug Rules 2009, wholesalers are given a place with the condition that they will be held accountable if counterfeit drugs are found with the retailers they supply.
|
Pakistan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |